Editas Medicine Inc (NASDAQ: EDIT) started the day on Wednesday, with a price increase of 6.22% at $2.22, before settling in for the price of $2.09 at the close. Taking a more long-term approach, EDIT posted a 52-week range of $0.91-$4.54.
The Healthcare sector firm’s twelve-monthly sales growth has been -1.48% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was -1.48%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 31.18%. This publicly-traded company’s shares outstanding now amounts to $97.62 million, simultaneously with a float of $97.12 million. The organization now has a market capitalization sitting at $216.71 million.
Editas Medicine Inc (EDIT) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Editas Medicine Inc’s current insider ownership accounts for 0.51%, in contrast to 45.45% institutional ownership. According to the most recent insider trade that took place on Dec 03 ’25, this organization’s EVP, CHIEF SCIENTIFIC OFFICER sold 713 shares at the rate of 2.15, making the entire transaction reach 1,535 in total value, affecting insider ownership by 68,777. Preceding that transaction, on Dec 03 ’25, Company’s CEO sold 5,603 for 2.15, making the whole transaction’s value amount to 12,064. This particular insider is now the holder of 269,087 in total.
Editas Medicine Inc (EDIT) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.34 per share during the current fiscal year.
Editas Medicine Inc’s EPS increase for this current 12-month fiscal period is 31.18% and is forecasted to reach -1.13 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 28.82% through the next 5 years, which can be compared against the -1.48% growth it accomplished over the previous five years trading on the market.
Editas Medicine Inc (NASDAQ: EDIT) Trading Performance Indicators
Let’s observe the current performance indicators for Editas Medicine Inc (EDIT). It’s Quick Ratio in the last reported quarter now stands at 2.86. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 4.67.
In the same vein, EDIT’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.38, a figure that is expected to reach -0.23 in the next quarter, and analysts are predicting that it will be -1.13 at the market close of one year from today.
